Ebola outbreak in Democratic Republic of Congo escalates globally

Five weeks after its official declaration, the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) continues to spiral out of control. Despite intensified response efforts, the virus persists, crossing borders and claiming lives at an alarming rate.

Intensified response efforts yet insufficient

Significant progress has been made in scaling up the emergency response. Treatment capacity has expanded dramatically, with isolation beds increasing from fewer than 10 to over 500 across 19 health facilities in affected zones. Diagnostic capabilities have also surged, from just 30 daily tests at the outbreak’s onset to over 2,000 daily tests conducted in nine laboratories spanning three provinces. To date, more than 100 recoveries have been recorded, demonstrating that early intervention can save lives.

However, the overall toll remains devastating: 1,094 confirmed cases and 277 deaths reported so far. According to Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), the epidemic continues to outpace containment efforts. Contact tracing remains inadequate, isolation facilities remain insufficient, and safe burials remain a daily challenge in communities plagued by mistrust or inaccessibility.

A virus that ignores borders

The outbreak has now spread far beyond the Congolese provinces of Ituri, North Kivu, and South Kivu. Neighboring Uganda has reported 20 confirmed cases and two deaths, all linked to the Congolese strain. Even more alarmingly, France has confirmed its first case on European soil: a humanitarian doctor from the ALIMA NGO, who had recently returned from a mission in the DRC, tested positive for the Ebola Bundibugyo virus. The patient, currently receiving specialized care, is in stable condition. An epidemiological investigation is underway to identify and monitor contacts.

This case underscores the sacrifices made by frontline healthcare workers. Nearly 80 health workers have been infected since the crisis began, prompting the WHO to urge states to ensure secure deployment conditions for humanitarian personnel, including the possibility of rapid medical evacuation in case of contamination.

Structural obstacles hamper containment

Beyond health-related challenges, the response faces structural barriers that impede every intervention. Border closures hinder the movement of teams and equipment. Security incidents are escalating in a region plagued by decades of armed conflict. Meanwhile, funding remains critically delayed, despite a continental response plan launched by the WHO and Africa CDC, valued at $518 million.

A glimmer of hope has emerged: a clinical trial evaluating two antiviral treatments, MBP134 and remdesivir, is set to begin next week in the DRC. Led by a consortium including the Congolese National Institute of Biomedical Research, ALIMA, the University of Oxford, and the WHO, and supported by donations from the United States and Gilead Sciences, this trial could mark a turning point in the fight against an epidemic that, five weeks after its onset, remains far from contained.